Interfering with key steps involvedin prion conversion could facilitate the rational design of therapeuticstrategies to prevent PrPSc formation.26,27 Application of anti-PrPC antibodies suppresses prionreplication in experimental animal models, presumably by stabilizingPrPC conformation.28 Major drawbacksof immunotherapy to cure TSE are immune tolerance, neurotoxic sideeffects and their limited ability to cross the blood–brainbarrier (BBB).29−32. Here, PRNP is linked to human prion disease.